NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity today upgraded shares of Quest Diagnostics and Laboratory Corporation of America to Buy ratings on expectations that visits to primary care physicians and laboratory testing will increase in 2015 over 2014 levels. 

Analyst Mark Massaro upgraded the ratings for both companies from prior Hold ratings. He also increased his price target on Quest to $82 from an earlier $63 target, and the price target on LabCorp to $145 from $100. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.